Avita Medical (RCEL) Receives a Buy from Oppenheimer

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Avita Medical (RCELResearch Report) yesterday and set a price target of $45.00. The company’s shares closed last Thursday at $26.36.

According to TipRanks.com, DeGeeter is a top 100 analyst with an average return of 72.1% and a 67.6% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Ionis Pharmaceuticals, and Cellectar Biosciences.

Avita Medical has an analyst consensus of Moderate Buy, with a price target consensus of $43.00, representing a 60.3% upside. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $41.00 price target.

See today’s analyst top recommended stocks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Avita Medical Ltd. engages in the development and distribution of regenerative and respiratory medicine and treatments. It operates through the following segments: Asia Pacific, Europe, and Americas. The Asia Pacific, Europe, and Americas segments involve in the sale of RECELL Devices. The company was founded on December 21, 1992 and is headquartered in Royston, the United Kingdom.